{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:24Z","timestamp":1786979604559,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Hope Run Special Fund of Cancer Foundation of China","award":["LC2017B17"],"award-info":[{"award-number":["LC2017B17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00066-022-01958-7","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T06:04:24Z","timestamp":1653890664000},"page":"949-957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antiemetic prophylaxis for chemoradiotherapy-induced nausea and vomiting in locally advanced head and neck squamous cell carcinoma: a\u00a0prospective phase\u00a0II trial"],"prefix":"10.1007","volume":"198","author":[{"given":"Zekun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"1958_CR1","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari\u00a0RM, Aapro\u00a0M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N\u00a0Engl J Med 374:1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"issue":"25","key":"1958_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"2017","author":"J Herrstedt","year":"2016","unstructured":"Herrstedt\u00a0J, Roila\u00a0F, Warr\u00a0D et\u00a0al (2016) Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer 2017(25):277\u2013288. https:\/\/doi.org\/10.1007\/s00520-016-3313-0","journal-title":"Support Care Cancer"},{"key":"1958_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi\u00a0Y, Chan\u00a0S, McFarlane\u00a0T et al (2019) ASCO, NCCN, MASCC\/ESMO: a\u00a0comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27:87\u201395. https:\/\/doi.org\/10.1007\/s00520-018-4464-y","journal-title":"Support Care Cancer"},{"key":"1958_CR4","doi-asserted-by":"publisher","first-page":"893013","DOI":"10.1155\/2015\/893013","volume":"2015","author":"P Feyer","year":"2015","unstructured":"Feyer\u00a0P, Jahn\u00a0F, Jordan\u00a0K (2015) Prophylactic management of radiation-induced nausea and vomiting. Biomed Res Int 2015:893013. https:\/\/doi.org\/10.1155\/2015\/893013","journal-title":"Biomed Res Int"},{"key":"1958_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00520-008-0445-x","volume":"17","author":"A Enblom","year":"2009","unstructured":"Enblom\u00a0A, Bergius Axelsson\u00a0B, Steineck\u00a0G et al (2009) One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 17:23\u201332. https:\/\/doi.org\/10.1007\/s00520-008-0445-x","journal-title":"Support Care Cancer"},{"key":"1958_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1080\/14656566.2016.1202923","volume":"17","author":"CH Ruhlmann","year":"2016","unstructured":"Ruhlmann\u00a0CH, Herrstedt\u00a0J (2016) New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting. Expert Opin Pharmacother 17:1623\u20131629. https:\/\/doi.org\/10.1080\/14656566.2016.1202923","journal-title":"Expert Opin Pharmacother"},{"key":"1958_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00066-010-2196-0","volume":"187","author":"I Fraunholz","year":"2011","unstructured":"Fraunholz\u00a0I, Grau\u00a0K, Weiss\u00a0C, Rodel\u00a0C (2011) Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy. Strahlenther Onkol 187:1\u20136. https:\/\/doi.org\/10.1007\/s00066-010-2196-0","journal-title":"Strahlenther Onkol"},{"key":"1958_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.radonc.2009.11.001","volume":"94","author":"E Maranzano","year":"2010","unstructured":"Maranzano\u00a0E, De Angelis\u00a0V, Pergolizzi\u00a0S et\u00a0al (2010) A prospective observational trial on emesis in radiotherapy: analysis of 1020\u00a0patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 94:36\u201341. https:\/\/doi.org\/10.1016\/j.radonc.2009.11.001","journal-title":"Radiother Oncol"},{"key":"1958_CR9","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","volume":"29","author":"S Grunberg","year":"2011","unstructured":"Grunberg\u00a0S, Chua\u00a0D, Maru\u00a0A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J\u00a0Clin Oncol 29:1495\u20131501. https:\/\/doi.org\/10.1200\/JCO.2010.31.7859","journal-title":"J Clin Oncol"},{"key":"1958_CR10","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","volume":"32","author":"KK Ang","year":"2014","unstructured":"Ang\u00a0KK, Zhang\u00a0Q, Rosenthal\u00a0DI et\u00a0al (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J\u00a0Clin Oncol 32:2940\u20132950. https:\/\/doi.org\/10.1200\/JCO.2013.53.5633","journal-title":"J Clin Oncol"},{"key":"1958_CR11","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","volume":"32","author":"PF Nguyen-Tan","year":"2014","unstructured":"Nguyen-Tan\u00a0PF, Zhang\u00a0Q, Ang\u00a0KK et al (2014) Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J\u00a0Clin Oncol 32:3858\u20133866. https:\/\/doi.org\/10.1200\/JCO.2014.55.3925","journal-title":"J Clin Oncol"},{"key":"1958_CR12","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1200\/jco.2017.74.9457","volume":"36","author":"V Noronha","year":"2018","unstructured":"Noronha\u00a0V, Joshi\u00a0A, Patil\u00a0VM et al (2018) Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J\u00a0Clin Oncol 36:1064\u20131072. https:\/\/doi.org\/10.1200\/jco.2017.74.9457","journal-title":"J Clin Oncol"},{"key":"1958_CR13","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1002\/cncr.32179","volume":"125","author":"VM Patil","year":"2019","unstructured":"Patil\u00a0VM, Noronha\u00a0V, Joshi\u00a0A et\u00a0al (2019) A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer 125:3184\u20133197. https:\/\/doi.org\/10.1002\/cncr.32179","journal-title":"Cancer"},{"key":"1958_CR14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ijrobp.2015.04.037","volume":"92","author":"F Jahn","year":"2015","unstructured":"Jahn\u00a0F, Riesner\u00a0A, Jahn\u00a0P et al (2015) Addition of the neurokinin-1-receptor antagonist (RA) aprepitant to a\u00a05-hydroxytryptamine-RA and dexamethasone in the prophylaxis of nausea and vomiting due to radiation therapy with concomitant cisplatin. Int J Radiat Oncol Biol Phys 92:1101\u20131107. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.037","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1958_CR15","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1007\/s00520-016-3306-z","volume":"24","author":"S Hanawa","year":"2016","unstructured":"Hanawa\u00a0S, Mitsuhashi\u00a0A, Matsuoka\u00a0A et al (2016) Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a\u00a0phase II study. Support Care Cancer 24:4633\u20134638. https:\/\/doi.org\/10.1007\/s00520-016-3306-z","journal-title":"Support Care Cancer"},{"key":"1958_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.12788\/jcso.0245","volume":"14","author":"RM Navari","year":"2016","unstructured":"Navari\u00a0RM, Nagy\u00a0CK, Le-Rademacher\u00a0J, Loprinzi\u00a0CL (2016) Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J\u00a0Community Support Oncol 14:141\u2013147. https:\/\/doi.org\/10.12788\/jcso.0245","journal-title":"J Community Support Oncol"},{"key":"1958_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s1470-2045(15)00615-4","volume":"17","author":"CH Ruhlmann","year":"2016","unstructured":"Ruhlmann\u00a0CH, Christensen\u00a0TB, Dohn\u00a0LH et al (2016) Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5\u00a0weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a\u00a0multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol 17:509\u2013518. https:\/\/doi.org\/10.1016\/s1470-2045(15)00615-4","journal-title":"Lancet Oncol"},{"key":"1958_CR18","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00520-016-3540-4","volume":"25","author":"S Ades","year":"2017","unstructured":"Ades\u00a0S, Halyard\u00a0M, Wilson\u00a0K et\u00a0al (2017) Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT). Support Care Cancer 25:1503\u20131510. https:\/\/doi.org\/10.1007\/s00520-016-3540-4","journal-title":"Support Care Cancer"},{"key":"1958_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1748-717x-9-56","volume":"9","author":"J Yi","year":"2014","unstructured":"Yi\u00a0J, Huang\u00a0X, Gao\u00a0L et al (2014) Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol 9:56. https:\/\/doi.org\/10.1186\/1748-717x-9-56","journal-title":"Radiat Oncol"},{"key":"1958_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.radonc.2015.07.041","volume":"117","author":"CL Brouwer","year":"2015","unstructured":"Brouwer\u00a0CL, Steenbakkers\u00a0RJHM, Bourhis\u00a0J et al (2015) CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol 117:83\u201390. https:\/\/doi.org\/10.1016\/j.radonc.2015.07.041","journal-title":"Radiother Oncol"},{"key":"1958_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00520-016-3449-y","volume":"25","author":"LH Einhorn","year":"2017","unstructured":"Einhorn\u00a0LH, Rapoport\u00a0B, Navari\u00a0RM et al (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303\u2013308. https:\/\/doi.org\/10.1007\/s00520-016-3449-y","journal-title":"Support Care Cancer"},{"key":"1958_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pst.541","volume":"11","author":"S Englert","year":"2012","unstructured":"Englert\u00a0S, Kieser\u00a0M (2012) Adaptive designs for single-arm phase II trials in oncology. Pharm Stat 11:241\u2013249. https:\/\/doi.org\/10.1002\/pst.541","journal-title":"Pharm Stat"},{"key":"1958_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ijgo.2015.05.030","volume":"131","author":"R Kawaguchi","year":"2015","unstructured":"Kawaguchi\u00a0R, Tanase\u00a0Y, Haruta\u00a0S et\u00a0al (2015) Addition of aprepitant to standard therapy for prevention of nausea and vomiting among patients with cervical cancer undergoing concurrent chemoradiotherapy. Int J Gynaecol Obstet 131:312\u2013313. https:\/\/doi.org\/10.1016\/j.ijgo.2015.05.030","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 1","key":"1958_CR24","doi-asserted-by":"publisher","first-page":"E2151","DOI":"10.1002\/hed.24026","volume":"38","author":"P Strojan","year":"2016","unstructured":"Strojan\u00a0P, Vermorken\u00a0JB, Beitler\u00a0JJ et\u00a0al (2016) Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck 38(Suppl 1):E2151\u2013E2158. https:\/\/doi.org\/10.1002\/hed.24026","journal-title":"Head Neck"},{"key":"1958_CR25","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1200\/jco.2004.07.962","volume":"22","author":"KK Ang","year":"2004","unstructured":"Ang\u00a0KK (2004) Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: Are we addressing burning subjects? J\u00a0Clin Oncol 22:4657\u20134659. https:\/\/doi.org\/10.1200\/jco.2004.07.962","journal-title":"J Clin Oncol"},{"key":"1958_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01467","author":"X-Y Li","year":"2022","unstructured":"Li\u00a0X\u2011Y, Luo\u00a0D\u2011H, Guo\u00a0L et al (2022) Deintensified chemoradiotherapy for pretreatment Epstein-Barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/jco.21.01467","journal-title":"J Clin Oncol"},{"key":"1958_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s1470-2045(18)30104-9","volume":"19","author":"L-Q Tang","year":"2018","unstructured":"Tang\u00a0L\u2011Q, Chen\u00a0D\u2011P, Guo\u00a0L et al (2018) Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II\u2013IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 19:461\u2013473. https:\/\/doi.org\/10.1016\/s1470-2045(18)30104-9","journal-title":"Lancet Oncol"},{"key":"1958_CR28","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh\u00a0PJ, Grunberg\u00a0SM, Gralla\u00a0RJ et al (2003) The oral neurokinin\u20111 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a\u00a0multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the aprepitant protocol 052 study group. J\u00a0Clin Oncol 21:4112\u20134119. https:\/\/doi.org\/10.1200\/JCO.2003.01.095","journal-title":"J Clin Oncol"},{"key":"1958_CR29","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli\u00a0S, Rodrigues-Pereira\u00a0J, Carides\u00a0AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a\u00a0randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090\u20133098. https:\/\/doi.org\/10.1002\/cncr.11433","journal-title":"Cancer"},{"key":"1958_CR30","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00520-017-3585-z","volume":"25","author":"SM Bosnjak","year":"2017","unstructured":"Bosnjak\u00a0SM, Gralla\u00a0RJ, Schwartzberg\u00a0L (2017) Prevention of chemotherapy-induced nausea: the role of neurokinin\u20111 (NK1) receptor antagonists. Support Care Cancer 25:1661\u20131671. https:\/\/doi.org\/10.1007\/s00520-017-3585-z","journal-title":"Support Care Cancer"},{"key":"1958_CR31","doi-asserted-by":"publisher","first-page":"e24122","DOI":"10.1200\/JCO.2020.38.15_suppl.e24122","volume":"38","author":"H D\u2019Souza","year":"2020","unstructured":"D\u2019Souza\u00a0H, Noronha\u00a0V, Patil\u00a0VM et\u00a0al (2020) Aprepitant in weekly cisplatin with radiation in head and neck cancer: Is it required? J\u00a0Clin Oncol 38:e24122\u2013e24122","journal-title":"J Clin Oncol"},{"key":"1958_CR32","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1634\/theoncologist.2017-0015","volume":"22","author":"P Szturz","year":"2017","unstructured":"Szturz\u00a0P, Wouters\u00a0K, Kiyota\u00a0N et al (2017) Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist 22:1056\u20131066. https:\/\/doi.org\/10.1634\/theoncologist.2017-0015","journal-title":"Oncologist"},{"key":"1958_CR33","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy\u00a0J, Chiew\u00a0KS, Galica\u00a0J et\u00a0al (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011\u20131015. https:\/\/doi.org\/10.1038\/sj.bjc.6603048","journal-title":"Br J Cancer"},{"key":"1958_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jpainsymman.2005.08.008","volume":"30","author":"CC Liaw","year":"2005","unstructured":"Liaw\u00a0CC, Wang\u00a0CH, Chang\u00a0HK et al (2005) Cisplatin-related hiccups: male predominance, induction by dexamethasone, and protection against nausea and vomiting. J\u00a0Pain Symptom Manage 30:359\u2013366. https:\/\/doi.org\/10.1016\/j.jpainsymman.2005.08.008","journal-title":"J Pain Symptom Manage"},{"key":"1958_CR35","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1634\/theoncologist.2017-0129","volume":"22","author":"SI Go","year":"2017","unstructured":"Go\u00a0SI, Koo\u00a0DH, Kim\u00a0ST et al (2017) Antiemetic corticosteroid rotation from dexamethasone to methylprednisolone to prevent dexamethasone-induced hiccup in cancer patients treated with chemotherapy: a randomized, single-blind, crossover phase III trial. Oncologist 22:1354\u20131361. https:\/\/doi.org\/10.1634\/theoncologist.2017-0129","journal-title":"Oncologist"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01958-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-022-01958-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01958-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:50:00Z","timestamp":1744185000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-022-01958-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1958"],"URL":"https:\/\/doi.org\/10.1007\/s00066-022-01958-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the title was incorrectly given as \u201cAntiemetic prophylaxis for chemoradiotherapy-induced nausea and vomiting in locally advanced head and heck squamous cell carcinoma: a\u00a0prospective phase\u00a0II trial\u201d but should have been \u201cAntiemetic prophylaxis for chemoradiotherapy-induced nausea and vomiting in locally advanced head and neck squamous cell carcinoma: a\u00a0prospective phase\u00a0II trial\u201d.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Z.\u00a0Wang, W.\u00a0Liu, J.\u00a0Zhang, X.\u00a0Chen, J.\u00a0Wang, K.\u00a0Wang, Y.\u00a0Qu, X.\u00a0Huang, J.\u00a0Luo, J.\u00a0Xiao, G.\u00a0Xu, L.\u00a0Gao, J.\u00a0Yi, and Y.\u00a0Zhang declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Approval No.17-115\/1371). Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}